Ortho Regenerative Technologies Inc. is an emerging orthobiologics company dedicated to the development of novel therapeutic tissue repair technologies to dramatically improve the success rate of orthopedic musculoskeletal surgeries.
We are committed to improving patients' lives through increasing the success rates of surgeries for soft tissue injuries. Our proprietary RESTORE technology platform, is a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. Ortho-R, our lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment. Ortho-R, our proprietary Chitosan-PRP combination implant can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention.
Our commercialization strategy involves a rapid development of treatments for both rotator cuff injuries in the shoulder and meniscus injuries of the knee joint, with an initial focus on the highly developed US Sports Medicine market. Other countries will follow shortly thereafter.